Early administration of the second surfactant dose in preterm infants with severe respiratory distress syndrome

Simple item page
dc.contributor.buuauthorKöksal, Nilgün
dc.contributor.buuauthorAkpınar, Reyhan
dc.contributor.buuauthorÇetinkaya, Merih
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Neonatoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Pediatri Anabilim Dalı.tr_TR
dc.contributor.scopusid7003323615tr_TR
dc.contributor.scopusid35797899400tr_TR
dc.contributor.scopusid23994946300tr_TR
dc.date.accessioned2022-02-25T13:24:59Z
dc.date.available2022-02-25T13:24:59Z
dc.date.issued2009
dc.description.abstractThe aim of this study was to determine whether early administration (2 hours after the first surfactant dose) of the second surfactant dose would be superior to late surfactant treatment (6 hours after the first surfactant dose) in preterm infants with severe respiratory distress syndrome. Between June 2003 and March 2005, 40 newborns born with respiratory distress syndrome in Uludag University Hospital were investigated in this prospective study. The inclusion criteria for the recruitment of the infants were: age <= 2 hours, birth weight between 600-2500 g, gestational age between 24-36 weeks, X-ray consistent with respiratory distress syndrome, and need for mechanical ventilation with inspiratory oxygen fraction >= 0.4 and mean airway pressure >= 7 cm H(2)O to obtain arterial pressure of oxygen between 70-80 mmHg. Infants with lethal congenital anomalies or being treated with high-frequency oscillatory ventilation were excluded from the study. Birth weight, gestational age, gender, and Apgar scores were recorded and complications of the surfactant therapy were examined. Twenty boys and 20 girls were enrolled in the study. The first surfactant dose was administered in the first hour of life in all infants. The second surfactant dose was given 2 hours after the first dose in 20 of them and 6 hours after the first dose in the other 20. Infants in both groups (early versus late) were similar with respect to gestational age, birth weight, gender, and the rate of prenatal corticosteroids. There were also no significant differences between the two groups in terms of the response to surfactant therapy and complications. The results of this study show that administration of the second surfactant dose earlier is as effective as late administration, and it may be suggested that the second surfactant dose can be applied earlier in severe respiratory distress syndrome.en_US
dc.identifier.citationKöksal, N. vd. (2009). "Early administration of the second surfactant dose in preterm infants with severe respiratory distress syndrome". Turkish Journal of Pediatrics, 51(6), 556-564.tr_TR
dc.identifier.endpage564tr_TR
dc.identifier.issn0041-4301
dc.identifier.issue6tr_TR
dc.identifier.pubmed20196389tr_TR
dc.identifier.scopus2-s2.0-76649111735tr_TR
dc.identifier.startpage556tr_TR
dc.identifier.urihttp://hdl.handle.net/11452/24670
dc.identifier.volume51tr_TR
dc.identifier.wos000274692900006tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherTürk Pediatri Dergisitr_TR
dc.relation.journalTurkish Journal of Pediatricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectExogenous surfactanten_US
dc.subjectPrematurityen_US
dc.subjectRespiratory distress syndromeen_US
dc.subjectHyaline-membrane diseaseen_US
dc.subject30 weeks gestationen_US
dc.subjectBronchopulmonary dysplasiaen_US
dc.subjectPulmonary hemorrhageen_US
dc.subjectPremature-infantsen_US
dc.subjectRandomized-trialen_US
dc.subjectLung surfactanten_US
dc.subjectAir leaken_US
dc.subjectTherapyen_US
dc.subjectLessen_US
dc.subjectPediatricsen_US
dc.subject.emtreeBeractanten_US
dc.subject.emtreeCorticosteroiden_US
dc.subject.emtreeDexamethasoneen_US
dc.subject.emtreeFurosemideen_US
dc.subject.emtreeInotropic agenten_US
dc.subject.emtreeOxygenen_US
dc.subject.emtreeSalbutamolen_US
dc.subject.emtreeSurfactanten_US
dc.subject.emtreeAirway pressureen_US
dc.subject.emtreeApgar scoreen_US
dc.subject.emtreeArterial pressureen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeArtificial ventilationen_US
dc.subject.emtreeBirth weighten_US
dc.subject.emtreeBrain hemorrhageen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeControlled clinical trialen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDisease severityen_US
dc.subject.emtreeDosage schedule comparisonen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeEncephalomalaciaen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGestational ageen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLung dysplasiaen_US
dc.subject.emtreeLung emphysemaen_US
dc.subject.emtreeLung hemorrhageen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNecrotizing enterocolitisen_US
dc.subject.emtreeNeonatal respiratory distress syndromeen_US
dc.subject.emtreeNewbornen_US
dc.subject.emtreePatent ductus arteriosusen_US
dc.subject.emtreePneumothoraxen_US
dc.subject.emtreePrematurityen_US
dc.subject.emtreeProspective studyen_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeX rayen_US
dc.subject.meshBiological productsen_US
dc.subject.meshDose-response relationship, drugen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-up studiesen_US
dc.subject.meshGestational ageen_US
dc.subject.meshHumansen_US
dc.subject.meshInfant, newbornen_US
dc.subject.meshInfant, prematureen_US
dc.subject.meshMaleen_US
dc.subject.meshOxygen consumptionen_US
dc.subject.meshProspective studiesen_US
dc.subject.meshPulmonary surfactantsen_US
dc.subject.meshRespiratory distress syndrome, newbornen_US
dc.subject.meshTime factorsen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.scopusPositive End Expiratory Pressure; Poractant; Prematurityen_US
dc.subject.wosPediatricsen_US
dc.titleEarly administration of the second surfactant dose in preterm infants with severe respiratory distress syndromeen_US
dc.typeArticle
dc.wos.quartileQ4en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Köksal_vd_2009.pdf
Size:
184.73 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus